BRCA1 and familial pancreatic carcinoma: The newly reported outcomes of the POLO (Pancreatic Cancer Olaparib Ongoing) trial (NCT02184195) for patients with metastatic pancreatic cancer that had not progressed during platinum-based chemotherapy and a BRCA1 or BRCA2 mutation have indicated that olaparib can be used for maintenance therapy for pancreatic cancer.